Cortical-basal Ganglionic Degeneration (CBGD) clinical trials at UCSF
1 in progress, 1 open to new patients
open to eligible people ages 40–80
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.
San Francisco, California and other locations